You are here

TGFβ signaling and Variation in AML

A new STEM CELLS article from the lab of Takafumi Yokota (Osaka University, Japan) reports autonomous TGFβ signaling as one of the molecular mechanisms underlying the heterogeneity and variability of leukemia stem cells (LSCs) associated with human acute myeloid leukemia (AML). Shingai et al. also note that mechanisms promoting the heterogeneity and variability of LSCs may also represent therapeutic targets against intractable AML.